September marks the beginning of a new season and is important for another reason: Menopause Awareness Month. When women enter menopause, they experience many physical changes, some such as hot flashes and night sweats are widely known and are easier to discuss. However, other changes are more difficult to speak.
However, I didn't know that his experience was actually a medical condition called vulvar and vaginal atrophy (VVA). After menopause, hormonal changes can lead to physical changes in the vagina, including loss of vaginal tissue, loss of lubrication and loss of flexibility. About 50 percent of postmenopausal women suffer from AVV, which can cause symptoms such as dryness, irritation, painful urination and painful sexual intercourse. While lubricants temporarily relieve pain with sex, they do not treat the underlying cause.
"I don't think women feel comfortable talking about their symptoms, which is unfortunate because painful sex due to menopause is not an inevitable part of aging," Linda said.
Linda's practicing nurse prescribed INTRAROSA® (prasterone), vaginal inserts for moderate to severe painful sex due to menopause. Prescription treatments such as INTRAROSE help to treat the underlying cause of painful sex after menopause and help relieve pain when taken as directed.
"Painful sex due to menopause is common and treatable," said Linda's practicing nurse, Dr. Lisa Chism DNP, APRN, NCMP, FAANP, Clinical Director, Women's Welfare Clinic, Karmanos Cancer Institute, and consultant for AMAG Pharmaceuticals. "I urge women to talk with their health care provider about their symptoms and find a suitable treatment option for them, just like Linda did."
Indication
INTRAROSE vaginal inserts are prescription medications used in women after menopause to treat moderate to severe pain during sexual intercourse caused by changes in and around the vagina that occur with menopause.
Important Safety Information
INTRAROSA is contraindicated in women with abnormal undiagnosed genital bleeding.
Estrogen is a metabolite of prasterone. The use of exogenous estrogens is contraindicated in women with a known or suspected history of breast cancer.
In four randomized, 12-week, placebo-controlled clinical trials, the most common adverse reaction with an incidence of 2% was vaginal discharge.
0 Comments